The FDA has approved Kerendia® (finerenone) to reduce the risk of cardiovascular death, hospitalization for HF, and urgent HF visits.

Researchers at the German Center for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of ...

The new Tempus software analyzes resting, non-ambulatory 12-lead ECG recordings to detect signs associated with having a low ...

A new study shows that people with a type of heart failure called HFpEF (heart failure with preserved ejection fraction) are ...

The US Food and Drug Administration (FDA) has granted 510 (k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF software. This software utilises AI to detect individuals with a low left ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced that it received 510(k) clearance ...

Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, Michigan is now ...

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...